Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from AbbVie

If You Invested $1000 In AbbVie 5 Years Ago, Here's How Much You Would Have Today

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 7.1% on an annualized basis producing an average annual return of 17.45%. Currently, AbbVie has a market capitalization of $260.97 billion.

What 8 Analyst Ratings Have To Say About AbbVie

What 8 Analyst Ratings Have To Say About AbbVie

Within the last quarter, AbbVie (NYSE:ABBV) has observed the following analyst ratings:

AbbVie Submits FDA Application For Continuous, 24-Hour Infusion Therapy For Parkinson's

AbbVie Submits FDA Application For Continuous, 24-Hour Infusion Therapy For Parkinson's

AbbVie Inc (NYSE:ABBV) submitted its FDA marketing application for ABBV-951, a solution of levodopa and carbidopa prodrugs being evaluated in advanced Parkinson’s patients who don’t respond well to oral therapy. AbbVie’s theory here revolves around using a continuous, 24-hour infusion of its therapy. The levodopa and carbidopa prodrugs are delivered in small doses…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Five Leading Stocks That At Least Double The S&P 500's Yield

Low-risk dividend stocks are coveted. Better yet, here are quality CAN-SLIM stocks that pay at least double the S&P 500 index's yield.

Investors Business Daily

AbbVie Whale Trades Spotted

Someone with a lot of money to spend has taken a bullish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

AbbVie, Cugene Ink Licensing Pact For Autoimmune & Inflammatory Disease Candidate

AbbVie Inc (ABBV) and Cugene Inc have announced an exclusive worldwide license option agreement for CUG252 for the potential treatment of autoimmune and inflammatory diseases. Cugene's lead candidate, CUG252, is an engineered IL-2 mutein designed to selectively activate and expand immune-suppressive Treg cells while reducing undesired IL-2 activity on other IL-2 receptor-expressing cells for autoimmune…

Why Tech Leader Regeneron Shouldn't Sweat Its AbbVie Rival — For Now

AbbVie could soon pressure Regeneron in eczema treatment, an analyst said Friday as Regeneron stock hit a ceiling at its 200-day line.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

AbbVie's Upadacitinib Shows Clinical Response In Crohn's Disease Maintenance Study At One Year

AbbVie's Upadacitinib Shows Clinical Response In Crohn's Disease Maintenance Study At One Year

AbbVie Inc (NYSE:ABBV) announced topline results from U-ENDURE Phase 3 maintenance study evaluating upadacitinib in adult patients with moderate to severe Crohn's disease. The trial included patients who had an inadequate response or were intolerant to conventional or biologic therapy. A significantly higher proportion of patients who received upadacitinib 15 mg or 30…

Top Funds Bet On These Stocks To Rise From Down Market

Top Funds Bet On These Stocks To Rise From Down Market

Led with a more-than $3 billion bet on Apple, the best mutual funds continue to invest heavily during this market correction.

Investors Business Daily

Stocks That Lift This JPMorgan Fund In Down Market

Stocks That Lift This JPMorgan Fund In Down Market

Most mutual funds have losses this year amid the market's sell-off. But JPMorgan Large Cap Value Fund is in positive territory. Here's why.

Investors Business Daily

Looking At AbbVie's Recent Whale Trades

Looking At AbbVie's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bullish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 10 strange trades.

U.S. FDA Approves AbbVie's RINVOQ® (upadacitinib) for Ankylosing Spondylitis (AS)

U.S. FDA Approves AbbVie's RINVOQ® (upadacitinib) for Ankylosing Spondylitis (AS)

The U.S. Food and Drug Administration (FDA) has approved AbbVie’s (NYSE: ABBV) RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment of adults with active ankylosing spondylitis (AS) .

Stock Market Down More Than 2%, Wiping Out Most Of Thursday's Rally; Amazon Hits Indexes

Stock Market Down More Than 2%, Wiping Out Most Of Thursday's Rally; Amazon Hits Indexes

The stock market sank to session lows in afternoon trading Friday as index losses topped 2%. The S&P 500 plunged 2.1% and undercut Thursday's lows, essentially wiping out almost all of that day's 2.5% rally. The Nasdaq composite slid 2.4%, though it is holding above Thursday's low. The Dow Jones…

Investors Business Daily

Stock Market Volatile; Apple, Facebook, Amazon Are Key Earnings, Tesla CEO Elon Musk Buys Twitter: Weekly Review

Stock Market Volatile; Apple, Facebook, Amazon Are Key Earnings, Tesla CEO Elon Musk Buys Twitter: Weekly Review

A market rally attempt is underway, but the major indexes lost ground. Apple and Facebook led key earnings. Elon Musk will buy Twitter.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Stock Market Drops On Lackluster Earnings From Amazon, Apple

The stock market dropped Friday after Amazon, Apple and others reported lackluster earnings and guidance.

AbbVie Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on AbbVie. Looking at options history for AbbVie (NYSE:ABBV) we detected 30 strange trades.

AbbVie Shares Fall On Mixed Bag Q1 Results, Cuts FY22 Profit Guidance

AbbVie Inc (NYSE:ABBV) reports Q1 adjusted EPS of $3.16, higher than the $2.89 reported a year ago and beating the consensus of $3.14. Overall sales increased 4.1% Y/Y (5.4% on an operational basis) to $13.54 billion, missing the consensus of $13.63 billion. The immunology portfolio generated $6.14 billion in sales, +6.9% (+8.1%…

Investors Business Daily

AbbVie Crumbles On Mixed Earnings, Slashes 2022 Profit Outlook

AbbVie beat first-quarter earnings forecasts, though sales came in light and the firm cut its 2022 profit guide. AbbVie stock fell Friday.

Get all your
news in one place.

100’s of premium titles.
One news app.

AbbVie: Q1 Earnings Insights

AbbVie (NYSE:ABBV) reported its Q1 earnings results on Friday, April 29, 2022 at 07:44 AM. Here's what investors need to know about the announcement.

Here's How Much You Would Have Made Owning AbbVie Stock In The Last 5 Years

AbbVie (NYSE:ABBV) has outperformed the market over the past 5 years by 6.18% on an annualized basis producing an average annual return of 18.59%. Currently, AbbVie has a market capitalization of $275.98 billion.

Preview: AbbVie's Earnings

AbbVie (NYSE:ABBV) is set to give its latest quarterly earnings report on Friday, 2022-04-29. Here's what investors need to know before the announcement. Analysts estimate that AbbVie will report an earnings per share (EPS) of $3.14.

The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates

Here's a roundup of top developments in the biotech space over the last 24 hours:

Analyst Ratings for AbbVie

Analysts have provided the following ratings for AbbVie (NYSE:ABBV) within the last quarter:

AbbVie Walks Away From Parkinson's Drug Pact With BioArctic

AbbVie Inc (NYSE:ABBV) has ended a research partnership with Sweden's BioArctic, backing out further development of an experimental Parkinson's disease drug and other related medicines. A clinicaltrials.gov listing for ABBV-0805 says a Phase I study is "Withdrawn (Strategic considerations)." The partnership between AbbVie and BioArctic, which began in 2016, was focused on antibody drugs…

AbbVie Whale Trades For April 19

Someone with a lot of money to spend has taken a bullish stance on AbbVie (NYSE:ABBV). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

1 … 7 8 9 10

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Dow Jones Industrial Average

Places

239,801 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play